 "Cipla's Goa manufacturing plant")
Drug major Cipla on Thursday announced the commercialisation of its RT-PCR test kit 'ViraGen' for COVID-19 in India, in partnership with Ubio Biotechnology Systems.
"This launch will help address the current testing services and capacity issues while reaffirming the company's ongoing expansion in the diagnostic space," Cipla said in a regulatory filing.
Cipla will launch ViraGen test kit in the country in partnership with Ubio Biotechnology Systems, the company stated.
The company will commence supply of the COVID-19 virus detection kit from May 25, 2021.
Umang Vohra, MD and Global CEO, Cipla, said, Cipla has been working relentlessly to ensure accessibility to treatments in this fight against COVID-19. Guided by our core purpose of 'Caring for Life', this partnership will enable us to reach out to more people across the country at a crucial time like now.
ViraGen is Cipla's third offering in the COVID-19 testing segment.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
